These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 37088950)

  • 21. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FasL gene knock-down therapy enhances the antiglioma immune response.
    Jansen T; Tyler B; Mankowski JL; Recinos VR; Pradilla G; Legnani F; Laterra J; Olivi A
    Neuro Oncol; 2010 May; 12(5):482-9. PubMed ID: 20406899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment.
    Ning W; Qiu Z; Ji X; Wang X; An Y; Wang S; Zhang H
    J Mol Neurosci; 2020 Oct; 70(10):1501-1511. PubMed ID: 32495005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
    Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L
    Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harnessing the immune system in glioblastoma.
    Brown NF; Carter TJ; Ottaviani D; Mulholland P
    Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
    Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():43-51. PubMed ID: 28720549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.
    Nejo T; Mende A; Okada H
    Jpn J Clin Oncol; 2020 Oct; 50(11):1231-1245. PubMed ID: 32984905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunology of low-grade gliomas.
    Haddad AF; Young JS; Oh JY; Okada H; Aghi MK
    Neurosurg Focus; 2022 Feb; 52(2):E2. PubMed ID: 35104791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
    Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
    Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.
    Sokratous G; Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2017 Nov; 13(11):2575-2582. PubMed ID: 28362548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives.
    Duerinck J; Tuyaerts S; Movahedi K; Neyns B
    Front Immunol; 2023; 14():1183641. PubMed ID: 37275902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma.
    Chen Z; Zhang W; Yan Z; Zhang M
    Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
    Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S
    Front Immunol; 2021; 12():729359. PubMed ID: 34566988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.
    Li L; Yang Z; Zheng Y; Chen Z; Yue X; Bian E; Zhao B
    BMC Neurol; 2022 May; 22(1):192. PubMed ID: 35614390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged response of recurrent
    Hwang H; Huang J; Khaddour K; Butt OH; Ansstas G; Chen J; Katumba RG; Kim AH; Leuthardt EC; Campian JL
    CNS Oncol; 2022 Mar; 11(1):CNS81. PubMed ID: 35043686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
    Xun Y; Yang H; Kaminska B; You H
    J Hematol Oncol; 2021 Oct; 14(1):176. PubMed ID: 34715891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.